Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell Lymphoma
Clinical trial NCT06415708 · UNKNOWN
Trial details
- NCT number
- NCT06415708
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-11-30
- Primary completion
- 2024-11-30
- Enrollment
- 134
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.